Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments

Publication Name: Poster, SABCS 2008

Author(s): Paul Roepman, Hugo Horlings, Oscar Krijgsman, Jolien Bueno-de-Mesquita, Richard Bender, Sabine Linn, Annuska Glas and Marc van de Vijver

In breast cancer patients the level of expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 is predictive for prognosis and/or treatment response. However, differences in assessment methods and interpretation can substantially affect the accuracy and reproducibility of the results. Previously, we have determined the association between immunohistochemistry (IHC) and mRNA levels for ER, PR and HER2, and have confirmed the accuracy of microarray readout on >450 samples [ref 1]. In the current study we describe the use of this microarray based readout on prospectively collected samples. We compared these readouts with multiple IHC and fluorescent in situ hybridization (FISH) assessments generated in various hospitals and a CLIA-certified reference laboratory and developed a microarray based test called TargetPrintTM.

See Poster